PhenoTec AG is a pharmaceutical research, service and consulting company. PhenoTec AG is involved in optimizing drug development by providing models to test new lead compounds in chronic lung and inflammatory diseases and infection including COVID infection. It also provides consulting and custom based advice to support of drug development projects. There is a growing need for novel and effective therapeutics in the field of inflammatory diseases, especially for allergic asthma and chronic obstructive pulmonary diseases (COPD) and exacerbation.
PhenoTec AG provides advice and technical support for a rapid and successful preclinical development for novel drug candidates to reach clinical phase studies. PhenoTec AG provides innovative solutions for preclinical studies and in vitro and in vivo studies. PhenoTec has an efficient networking with opinion leaders and scientists to ensure innovative new products and services.